News

Hosted on MSN15d
Sonnet BioTherapeutics reports positive results from ovarian cancer therapy trial
SON-1010 is Sonnet BioTherapeutics' lead programme and is designed to treat solid tumours, ovarian cancer and certain types of sarcoma. Earlier this year, the company expanded its Phase I SB101 trial ...
1STBIO and LigaChemBio Announce Strategic R&D and Licensing Option Agreement
Expanded collaboration leverages complementary expertise to unlock next-generation oncology therapeutics Focus on breakthrough ADC payloads and ...
Sonnet Releases Virtual Investor "What This Means" Segment
Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, of Sonnet discuss the recently announced safety data ...
La Grande Observer1mon
Latigo Biotherapeutics Closes $150 Million in Series B Financing to Advance Non-Opioid Pain Therapeutics
THOUSAND OAKS, Calif., March 17, 2025 /PRNewswire/ — Latigo Biotherapeutics (“Latigo”), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments that target ...
Yahoo Finance28d
FORE Biotherapeutics to Present Two Plixorafenib Abstracts at the American Association for Cancer Research Annual Meeting 2025
PHILADELPHIA, March 25, 2025--(BUSINESS WIRE)--FORE Biotherapeutics ... study evaluating plixorafenib in patients with various types of BRAF-mutated tumors. "Plixorafenib’s unique paradox ...
Nasdaq27d
Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas
Given the types of proteins induced in the TME ... of bispecific candidates using the FHAB platform. About Sonnet BioTherapeutics Holdings, Inc. Sonnet is an oncology-focused biotechnology ...